Immuneering
Stock Forecast, Prediction & Price Target
Immuneering Financial Estimates
Immuneering Revenue Estimates
Immuneering EBITDA Estimates
Immuneering Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $2.07M N/A | $316.95K -84.76% | $0 -100% | Avg: $1.08M Low: $1.08M High: $1.08M avg. 0% | Avg: $21.26M Low: $21.26M High: $21.26M avg. 1855.55% | Avg: $50.1M Low: $50.1M High: $50.1M avg. 135.57% | Avg: $56.45M Low: $56.45M High: $56.45M avg. 12.68% |
Net Income
% change YoY
| $-33.53M N/A | $-49.28M -46.95% | $-53.47M -8.50% | Avg: $-90.47M Low: $-69.05M High: $-29.83M avg. -69.20% | Avg: $-108.71M Low: $-77.00M High: $-23.58M avg. -20.15% | Avg: $-45.27M Low: $-45.27M High: $-45.27M avg. 58.35% | Avg: $-37.79M Low: $-37.79M High: $-37.79M avg. 16.52% |
EBITDA
% change YoY
| $-33.88M N/A | $-51.71M -52.61% | $-58.06M -12.27% | Avg: $-652.5K Low: $-652.5K High: $-652.5K avg. 98.87% | Avg: $-12.76M Low: $-12.76M High: $-12.76M avg. -1855.55% | Avg: $-30.06M Low: $-30.06M High: $-30.06M avg. -135.57% | Avg: $-33.87M Low: $-33.87M High: $-33.87M avg. -12.68% |
EPS
% change YoY
| -$1.27 N/A | -$1.87 -47.24% | -$1.88 -0.53% | Avg: -$1.83 Low: -$2.43 High: -$1.05 avg. 2.92% | Avg: -$1.94 Low: -$2.71 High: -$0.83 avg. -6.30% | Avg: -$1.59 Low: -$1.59 High: -$1.59 avg. 17.86% | Avg: -$1.33 Low: -$1.33 High: -$1.33 avg. 16.52% |
Operating Expenses
% change YoY
| $34.81M N/A | $51.90M 49.09% | $58.41M 12.54% | Avg: $12.39M Low: $12.39M High: $12.39M avg. -78.78% | Avg: $242.32M Low: $242.32M High: $242.32M avg. 1855.55% | Avg: $570.86M Low: $570.86M High: $570.86M avg. 135.57% | Avg: $643.26M Low: $643.26M High: $643.26M avg. 12.68% |
FAQ
What is Immuneering stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of -3.62% in 2025-2028.
We have gathered data from 4 analysts. Their low estimate is -69.05M, average is -90.47M and high is -29.83M.
What is Immuneering stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 500.95% in 2025-2028.
We have gathered data from 5 analysts. Their low revenue estimate is $1.08M, average is $1.08M and high is $1.08M.
What is Immuneering stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 7.75% in 2025-2028.
We have gathered data from 4 analysts. Their low earnings per share estimate is -$2.43, average is -$1.83 and high is $-1.05.
What is the best performing analyst?
In the last twelve months analysts have been covering Immuneering stock. The most successful analyst is Graig Suvannavejh.